Anesthetics News and Research

RSS

SYNERA can help prevent needle stick pain associated with superficial IVs

Galen US Incorporated today announced that the U.S. Food and Drug Administration (FDA) recently approved a labeling change that allows SYNERA® (lidocaine and tetracaine) topical patch to be used at home.

4 Jun 2014

IV-administered ketamine effective in patients with chronic PTSD

For the first time, evidence that a single dose of IV-administered ketamine was associated with the rapid reduction of symptoms of post-traumatic stress disorder in patients with chronic PTSD was demonstrated in a proof-of-concept, randomized, double blind crossover study, undertaken by researchers at the Icahn School of Medicine at Mount Sinai in New York City. These findings, according to Mount Sinai researchers, could be the first step toward developing new interventions for PTSD.

21 Apr 2014

Researchers develop novel assay to identify genes controlling pharynx regeneration in flatworms

As multicellular creatures go, planaria worms are hardly glamorous. To say they appear rudimentary is more like it. These tiny aquatic flatworms that troll ponds and standing water resemble brown tubes equipped with just the basics: a pair of beady light-sensing "eyespots" on their head and a feeding tube called the pharynx (which doubles as the excretory tract) that protrudes from a belly sac to suck up food.

11 Apr 2014

Ketamine offers novel treatment for patients with severe depression

New data show ketamine (a drug widely used for anaesthesia and pain relief) has a rapid antidepressant effect in some patients with severe depression. The first UK study of ketamine intravenous infusions in people with treatment-resistant depression was conducted by the Oxford Health NHS Foundation Trust and the University of Oxford.

3 Apr 2014

FDA approves additional manufacturing suite for Pacira’s EXPAREL

Pacira Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration approved an additional bulk manufacturing suite, referred to as Suite C, for EXPAREL (bupivacaine liposome injectable suspension). The suite is housed at the company's Science Center Campus in San Diego, where EXPAREL is currently manufactured.

31 Mar 2014

Baxter plans to create two independent global healthcare companies

Baxter International Inc. today announced plans to create two separate, independent global healthcare companies -- one focused on developing and marketing innovative biopharmaceuticals and the other on life-saving medical products. Both will be global leaders in their respective markets.

From Baxter International Inc. 27 Mar 2014

Patients with congenital disorders are urged to register with CMDIR to advance clinical trials

If you are affected by Malignant Hyperthermia, Congenital Muscular Dystrophies or Congenital Myopathy Subtypes, the Malignant Hyperthermia Association of the United States and the Cure Congenital Muscle Disease organization are asking for your help to enable research and clinical trials by registering with the Congenital Muscle Disease International Registry (CMDIR).

13 Mar 2014

Pacira Pharmaceuticals initiates Phase 3 clinical trial of EXPAREL in femoral nerve block

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the Phase 3 clinical trial assessing the safety and efficacy of EXPAREL® (bupivacaine liposome injectable suspension) in femoral nerve block for total knee arthroplasty met its primary efficacy endpoint.

27 Feb 2014

Viewpoints: 'Sham Surgery' for research; bigger hospitals may not bring better care

In a landmark study of a new cardiovascular device unveiled last month, patients received anesthetics, had a large-bore catheter inserted through a cut into one of their major arteries, and had dye injected into their bloodstream.

20 Feb 2014

New treatments for depression on the horizon

New insights into the physiological causes of depression are leading to treatments beyond common antidepressants such as Prozac and Zoloft, researchers are reporting in the in the journal Current Psychiatry.

15 Feb 2014

Sedation before nerve block significantly increases false-positive results, shows study

New research suggests that sedating patients before a nerve block needed to diagnose or treat chronic pain increases costs, risks and unnecessary surgeries, and sedation does nothing to increase patient satisfaction or long-term pain control.

13 Feb 2014

AP, Kaiser Permanente initiate clinical trial to evaluate the efficacy of Promescent lidocaine spray

Absorption Pharmaceuticals LLC in collaboration with Kaiser Permanente announced today the initiation of a clinical trial to evaluate the efficacy of Promescent lidocaine spray for men with premature ejaculation. This Phase III, double blind, placebo-controlled, randomized study will measure the intravaginal ejaculatory latency time for subjects aged 18 and older.

11 Dec 2013

Study reveals nearly 1 in every 100 anesthesiologist developed substance use disorder during training

According to a study conducted by Mayo Clinic and the American Board of Anesthesiology (ABA), nearly 1 in every 100 anesthesiology residents entering primary training from 1975 to 2009 developed substance use disorder (SUD) during training.

5 Dec 2013

TopPac® 20 ml prefillable polymer syringe for infusion therapy introduced by SCHOTT

SCHOTT expanded its range of TopPac polymer syringes to include a 20 milliliter (ml) format that can be used in combination with syringe pumps for infusion therapy. SCHOTT TopPac® prefillable syringes (PFS) simplify the infusion therapy preparation process and can ultimately reduce costs for pharmaceutical companies and health care facilities.

13 Nov 2013

MGH researchers identify probable mechanism for pain-induced cognitive impairment

The pain caused by a surgical incision may contribute to the risk of postoperative cognitive dysfunction, a sometimes transient impairment in learning and memory that affects a small but significant number of patients in the days following a surgical procedure.

7 Nov 2013

FDA approves Prior Approval Supplement for EMBEDA Extended Release Capsules CII

Pfizer Inc. announced today that the U.S. Food and Drug Administration has approved a Prior Approval Supplement for EMBEDA (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules CII.

4 Nov 2013

Study: Liposomal bupivacaine can provide longer-lasting nerve blocks

Can a new liposomal bupivacaine product provide long-lasting nerve block with a single injection? An initial study in humans shows promise-but also some "confusing results," reports the November issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

29 Oct 2013

Nelsons introduces new hemorrhoid cream

Nelsons, a 150 year old privately owned company and the UK's largest manufacturer of natural healthcare products, introduces Homeopathic H+Care™ Hemorrhoid Cream.

24 Oct 2013

Less-healthy patients more prone to recovery room complications

Complications in the recovery room decreased by 58 percent between 1990 and 2010, according to a study presented at the ANESTHESIOLOGY 2013 annual meeting. In a previous study completed in the late 1980s, recovery room complications occurred in 23.7 percent of the patients.

16 Oct 2013

New study on propofol drug may help develop effective anesthetics with fewer side effects

Researchers at Washington University School of Medicine in St. Louis and Imperial College London have identified the site where the widely used anesthetic drug propofol binds to receptors in the brain to sedate patients during surgery.

23 Sep 2013